Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | NRAS act mut |
| Therapy | Binimetinib |
| Indication/Tumor Type | skin melanoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| NRAS act mut | skin melanoma | sensitive | Binimetinib | Guideline | Actionable | Mektovi (binimetinib) is included in guidelines as subsequent therapy for patients with NRAS-mutant unresectable or metastatic cutaneous melanoma who did not benefit from prior immunotherapies (PMID: 39550033; ESMO.org). | detail... 39550033 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| ESMO Clinical Practice Guidelines | Full reference... | |
| (39550033) | Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. | Full reference... |